138 related articles for article (PubMed ID: 18689865)
1. About sorafenib in castration-resistant prostate cancer.
Colloca G; Checcaglini F; Venturino A
Ann Oncol; 2008 Oct; 19(10):1812-3; author reply 1813-1814. PubMed ID: 18689865
[No Abstract] [Full Text] [Related]
2. About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Aragon-Ching JB; Dahut WL
Ann Oncol; 2010 Jan; 21(1):183-4. PubMed ID: 19903718
[No Abstract] [Full Text] [Related]
3. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Beardsley EK; Hotte SJ; North S; Ellard SL; Winquist E; Kollmannsberger C; Mukherjee SD; Chi KN
Invest New Drugs; 2012 Aug; 30(4):1652-9. PubMed ID: 21785998
[TBL] [Abstract][Full Text] [Related]
4. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
[TBL] [Abstract][Full Text] [Related]
6. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract][Full Text] [Related]
7. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Steinbild S; Mross K; Frost A; Morant R; Gillessen S; Dittrich C; Strumberg D; Hochhaus A; Hanauske AR; Edler L; Burkholder I; Scheulen M
Br J Cancer; 2007 Dec; 97(11):1480-5. PubMed ID: 18040273
[TBL] [Abstract][Full Text] [Related]
8. Keratoacanthomas associated with sorafenib therapy.
Kong HH; Cowen EW; Azad NS; Dahut W; Gutierrez M; Turner ML
J Am Acad Dermatol; 2007 Jan; 56(1):171-2. PubMed ID: 17190642
[No Abstract] [Full Text] [Related]
9. Targeting ELF in therapy of liver cancer.
Cancer Biol Ther; 2007 Jul; 6(7):997. PubMed ID: 19358343
[No Abstract] [Full Text] [Related]
10. Sorafenib is active on lung metastases from synovial sarcoma.
Basso U; Brunello A; Bertuzzi A; Santoro A
Ann Oncol; 2009 Feb; 20(2):386-7. PubMed ID: 19211500
[No Abstract] [Full Text] [Related]
11. Objective response to sorafenib in advanced clear-cell sarcoma.
Mir O; Boudou-Rouquette P; Larousserie F; Babinet A; Dumaine V; Anract P; Goldwasser F
Ann Oncol; 2012 Mar; 23(3):807-809. PubMed ID: 22274882
[No Abstract] [Full Text] [Related]
12. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
13. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
14. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
15. Health-related quality of life and sorafenib.
Spinzi G; Terreni N
Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
[No Abstract] [Full Text] [Related]
16. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW
Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
[No Abstract] [Full Text] [Related]
17. Phase II studies in soft tissue sarcoma: time for reappraisal.
Sleijfer S
Oncologist; 2012; 17(2):154-6. PubMed ID: 22285964
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Kim DY; Han KH
J Gastroenterol Hepatol; 2011 Nov; 26(11):1585-6. PubMed ID: 22011294
[No Abstract] [Full Text] [Related]
19. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
20. Antiangiogenic therapy: not just for cancer anymore?
Shah VH; Bruix J
Hepatology; 2009 Apr; 49(4):1066-8. PubMed ID: 19330868
[No Abstract] [Full Text] [Related]
[Next] [New Search]